Clinical Trial of Protein Farnesylation Inhibitors Lonafarnib, Pravastatin and Zoledronic Acid in Children with Hutchinson-Gilford Progeria Syndrome

BACKGROUND: Hutchinson-Gilford progeria syndrome is an extremely rare, fatal, segmental premature aging syndrome caused by a mutation in LMNA yielding the farnesylated aberrant protein, progerin. Without progerin-specific treatment, death occurs at an average age of 14.6 years from an accelerated at...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Circulation
Prif Awduron: Gordon, Leslie B., Kleinman, Monica E, Massaro, Joe, D’Agostino, Ralph B., Shappell, Heather, Gerhard-Herman, Marie, Smoot, Leslie B., Gordon, Catherine M., Cleveland, Robert H., Nazarian, Ara, Snyder, Brian D., Ullrich, Nicole J., Silvera, V. Michelle, Liang, Marilyn G., Quinn, Nicolle, Miller, David T., Huh, Susanna Y., Dowton, Anne A., Littlefield, Kelly, Greer, Maya M., Kieran, Mark W.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943677/
https://ncbi.nlm.nih.gov/pubmed/27400896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.116.022188
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg